The LANDMARK trial continues to show positive outcomes for the TAVR valve made in India.

Physicians often tell AFib patients they should limit coffee consumption to protect their hearts. This new analysis, however, suggests that may not be necessary.

Researchers used AI-enabled software developed by Cleerly to evaluate the CCTA results of more than 6,000 patients. The software was consistently effective, identifying patients who may face an increased risk of poor outcomes. 

Procizumab was developed to change the trajectory of shock by addressing an underlying molecular driver rather than just managing symptoms.

Calcium in the coronary arteries is a known cardiac risk factor. However, new data suggest it may actually tell us more about a person's overall health than researchers previously believed. 

Researchers warned that “aggressive procedural modifications” should not be necessary during TAVR to mitigate the risk of prosthesis-patient mismatch. This appears to be true for patients receiving both self-expanding and balloon-expandable TAVR valves.

Although the drug can slow the progression of cognitive decline, it may have little impact on damage already done by AD prior to treatment.

Sports fans may actually be emotionally dependent on their team’s performance on a neural level, according to functional imaging data.